What happened with ICUI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
ICU Medical supplies the pumps, software and disposable products healthcare providers use to deliver fluids and medicines and access patients’ blood vessels. Consumables such as IV sets, connectors and catheters are its largest revenue source, followed by infusion systems. Hospitals and distributors buy most of its products; it also serves outpatient and home-care providers through direct sales and independent distributors worldwide.
The company also sells respiratory, anesthesia, monitoring and temperature-management products. It sells and distributes IV solutions on behalf of a joint venture controlled by Otsuka Pharmaceutical Factory America, while retaining a minority ownership interest in that venture.
One distributor supplies a substantial share of sales. Hospital purchasing also depends partly on contracts with large healthcare providers and group purchasing organizations, which negotiate purchases for member hospitals. Insurers and government programs do not reimburse ICU Medical’s products separately, so what they pay providers for care influences product demand and the prices customers will accept.
Medical-device rules restrict which products and uses the company may market. ICU Medical has submitted new versions of its MedFusion and CADD infusion pumps for FDA clearance to address a warning letter concerning modifications to existing devices; unresolved concerns could lead to sales restrictions or recalls.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
ICU Medical’s results hinge on hospital infusion demand and competition from B. Braun, while its IV-solutions business also depends on its joint venture with Otsuka Pharmaceutical Factory America.
BD competes with ICU Medical for hospitals’ and other healthcare providers’ purchases of infusion pumps and disposable infusion supplies. Watch BD’s pump safety and reliability news: ICU says its pump offering can also help sell more higher-margin infusion consumables.
Baxter competes with ICU Medical for hospital spending on infusion systems, IV administration sets and IV solutions. Baxter’s news on these products matters more to this rivalry than results from its other healthcare businesses.
Teleflex competes with ICU Medical to sell single-use medical supplies to hospitals and other healthcare providers, putting it against a business that generated 50% of ICU’s revenue in 2025. Watch Teleflex’s new disposable devices and their cost-effectiveness, both areas in which these suppliers compete.
AngioDynamics, Inc. competes with ICU Medical for hospital purchases of devices that give clinicians access to blood vessels, including catheters and ports. Its catheter and port launches are the news to watch for ICU’s vascular-access consumables, rather than its broader cancer-treatment portfolio.
Merit Medical competes with ICU Medical for hospitals’ and clinicians’ purchases of vascular-access devices and supplies used in procedures. Watch Merit’s new vascular-access products and procedural kits, where its offering overlaps ICU’s consumables business.
InfuSystem Holdings, Inc. is a buyer of ICU Medical’s ambulatory pumps for outpatient oncology; ICU supplied approximately 60% of the pumps it purchased in 2025. InfuSystem provides pumps and disposable supplies to oncology offices and outpatient chemotherapy clinics, billing payers, facilities of Medicare patients and patients, so its pump purchases are a concrete signal of customer demand for ICU.
Solventum competes with ICU Medical for hospital medical-supply purchases, including products that manage patient temperature and overlap ICU’s Vital Care range. Watch Solventum’s temperature-management products rather than its dental or healthcare-software results when assessing this competition.
Baxter International Inc. earningsBAX
Baxter’s report will show whether hospitals are buying more infusion systems, IV sets and IV solutions—the same markets where it competes with ICU Medical.
Focus on Baxter’s sales or demand commentary for infusion systems, IV sets and IV solutions, not its other healthcare businesses. Stronger demand in those products would show that hospital purchasing in the shared market is holding up, supporting the market ICU Medical competes in; weaker demand would signal pressure on that market, but would not establish that ICU lost orders.
Merit Medical Systems Inc earningsMMSI
Merit Medical’s report will show how hospitals and clinicians are buying vascular-access devices and supplies that overlap with ICU Medical’s consumables business.
Watch Merit Medical’s commentary on new vascular-access products and related supply demand. Stronger demand alongside uptake of new products would show that hospital purchasing in this device category is supported, leaving ICU Medical’s competing consumables in a healthier market; weak demand or limited uptake would point to a softer shared market, not prove ICU sales declined.
InfuSystem Holdings, Inc. earningsINFU
InfuSystem Holdings’ report will show whether this outpatient oncology provider is buying more of ICU Medical’s ambulatory pumps.
Look for InfuSystem Holdings’ comments on pump purchases or demand alongside changes in its pump business. More purchases or stronger pump demand would show this direct customer is expanding its use of ICU Medical equipment; fewer purchases or weaker demand would mean less order support from this customer, but one buyer cannot establish the trend across hospitals overall.
ICU Medical Inc earningsThis company
ICU Medical’s report will show whether growth in Consumables and Infusion Systems can offset weakness in Vital Care and keep improving margins.
Read sales in Consumables, Infusion Systems and Vital Care alongside gross and operating margins. Growth in Consumables and Infusion Systems with both margins rising would show that firmer demand is translating into profit; sales growth without improving margins would point to pricing or production costs still absorbing the gains. Continued weakness in total revenue or margins would mean the recovery remains limited.
